[go: up one dir, main page]

PE12598A1 - Formas zwitterionicas de trovafloxacina - Google Patents

Formas zwitterionicas de trovafloxacina

Info

Publication number
PE12598A1
PE12598A1 PE1996000633A PE00063396A PE12598A1 PE 12598 A1 PE12598 A1 PE 12598A1 PE 1996000633 A PE1996000633 A PE 1996000633A PE 00063396 A PE00063396 A PE 00063396A PE 12598 A1 PE12598 A1 PE 12598A1
Authority
PE
Peru
Prior art keywords
trovafloxacin
obtaining
pentahydrate
dry
main peaks
Prior art date
Application number
PE1996000633A
Other languages
English (en)
Inventor
Timothy Norris
David B Joseph
Douglas J M Allen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE12598A1 publication Critical patent/PE12598A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physical Water Treatments (AREA)
  • Processing Of Solid Wastes (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

CARACTERIZADAS PORQUE COMPRENDEN: 1) POLIMORFO P(I), NO HIGROSCOPICO; 2) POLIMORFO P(II), HIGROSCOPICO; 3) PENTAHIDRATO; CUYOS PATRONES DE DIFRACCION DE RAYOS X DE POLVO, COMPRENDEN PARA: 1) P(I), 15 PICOS PRINCIPALES, DE 6,9� 2U(Cu) A 26,3� 2U(Cu); 2) P(II), 8 PICOS PRINCIPALES, DE 8,4� 2U(Cu) A 26,1� 2U(Cu); 3) PENTAHIDRATO, 17 PICOS PRINCIPALES DE 6,6� 2U(Cu) A 29,5� 2U(Cu). TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LA FORMA METAESTABLE DEL ZWITTERION DE TROVAFLOXACINA, DE FORMULA (I), QUE COMPRENDE: A) TRATAR LA SAL ACIDA DE TROVAFLOXACINA CON UNA BASE HASTA UN pH DE 7,5 A 8,5 Y A UNA TEMPERATURA ELEVADA; O B) RETIRAR LOS GRUPO PROTECTOR AMINO Y/O CARBOXILO, OPCIONALMENTE PRESENTES EN LA TROVAFLOXACINA. ADEMAS SE REFIERE AL PROCEDIMIENTO DE PREPARACION DE LAS FORMAS ZWITTERIONICAS DE TROVAFLOXACINA, QUE COMPRENDEN: 1) TRATAR LA SOLUCION ACUOSA DE LA FORMA METAESTABLE CON: a) UN DISOLVENTE POLAR, LUEGO (d), OBTENIENDO P(I); b) UN DISOLVENTE APOLAR, LUEGO (d), OBTENIENDO P(II); c) AGUA, LUEGO (e), OBTENIENDO EL PENTAHIDRATO; d) ELIMINAR AZEOTROPICAMENTE EL AGUA RESIDUAL Y SECAR AL VACIO; e) SECAR CON AIRE CALIENTE, ELIMINAR LAS AGUAS MADRES Y SECAR A TEMPERATURA AMBIENTE; 2) TRATAR P(II) CON UN DISOLVENTE POLAR A REFLUJO, OBTENIENDO P(I). SON ANTIBIOTICOS PARA BACTERIAS GRAM POSITIVAS
PE1996000633A 1995-08-29 1996-08-26 Formas zwitterionicas de trovafloxacina PE12598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US297595P 1995-08-29 1995-08-29

Publications (1)

Publication Number Publication Date
PE12598A1 true PE12598A1 (es) 1998-03-20

Family

ID=21703460

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000633A PE12598A1 (es) 1995-08-29 1996-08-26 Formas zwitterionicas de trovafloxacina

Country Status (30)

Country Link
EP (1) EP0850060A1 (es)
JP (1) JP3188476B2 (es)
KR (1) KR100343909B1 (es)
CN (1) CN1190889A (es)
AP (1) AP636A (es)
AR (1) AR003985A1 (es)
AU (1) AU704115B2 (es)
BR (1) BR9609998A (es)
CA (1) CA2229786C (es)
CO (1) CO4480739A1 (es)
CZ (1) CZ56698A3 (es)
DZ (1) DZ2087A1 (es)
GT (1) GT199600072A (es)
HR (1) HRP960395B1 (es)
HU (1) HUP9900170A3 (es)
IL (1) IL122651A (es)
MA (1) MA23966A1 (es)
MY (1) MY113874A (es)
NO (1) NO309814B1 (es)
NZ (1) NZ312199A (es)
OA (1) OA10669A (es)
PE (1) PE12598A1 (es)
PL (1) PL325170A1 (es)
RU (1) RU2144921C1 (es)
SK (1) SK23898A3 (es)
TN (1) TNSN96109A1 (es)
TR (1) TR199800339T1 (es)
WO (1) WO1997007800A1 (es)
YU (1) YU48396A (es)
ZA (1) ZA967282B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1998000106A (es) 1997-08-01 1999-01-08 Pfizer Prod Inc Composiciones parenterales de alatroflaxacino
US7019142B2 (en) 1998-01-16 2006-03-28 Pfizer Inc. Process for preparing naphthyridones and intermediates
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino
US6114531A (en) * 1998-07-28 2000-09-05 Pfizer Inc. Process for preparing quinolone and naphthyridone carboxylic acids
HN1999000141A (es) * 1998-09-03 2000-06-19 Pfizer Prod Inc Procedimiento para preparar sales de trovafloxacina de adicion de acidos.
US6239141B1 (en) * 1999-06-04 2001-05-29 Pfizer Inc. Trovafloxacin oral suspensions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS274601B2 (en) * 1983-07-27 1991-09-15 Dainippon Pharmaceutical Co Method of 1,8-naphthyridine derivative production
NZ232091A (en) * 1989-01-16 1990-12-21 Bellon Labor Sa Roger 7-fluoro-8-(piperazin-1-yl)-4-oxo-1,4-dihydro-benzo(b)(1,8)naphthyridine-3-carboxylic acid derivatives, preparation and pharmaceutical compositions thereof
US5164402A (en) * 1989-08-16 1992-11-17 Pfizer Inc Azabicyclo quinolone and naphthyridinone carboxylic acids
US5939550A (en) 1995-06-15 1999-08-17 Pfizer Inc. Process for preparing derivatives of azabicyclo naphthyridine carboxylic acid comprising a dipeptide

Also Published As

Publication number Publication date
HRP960395B1 (en) 2001-12-31
YU48396A (sh) 1998-12-23
HRP960395A2 (en) 1998-06-30
AU6367696A (en) 1997-03-19
PL325170A1 (en) 1998-07-06
JPH10511692A (ja) 1998-11-10
RU2144921C1 (ru) 2000-01-27
OA10669A (en) 2000-11-06
IL122651A0 (en) 1998-08-16
SK23898A3 (en) 1999-05-07
BR9609998A (pt) 1999-07-06
EP0850060A1 (en) 1998-07-01
AU704115B2 (en) 1999-04-15
DZ2087A1 (fr) 2002-07-22
HUP9900170A2 (hu) 1999-05-28
IL122651A (en) 2000-02-17
TR199800339T1 (xx) 1998-06-22
TNSN96109A1 (fr) 2005-03-15
NO309814B1 (no) 2001-04-02
CO4480739A1 (es) 1997-07-09
ZA967282B (en) 1998-03-02
CA2229786C (en) 2002-02-19
AP636A (en) 1998-04-09
NZ312199A (en) 1999-06-29
CA2229786A1 (en) 1997-03-06
JP3188476B2 (ja) 2001-07-16
CZ56698A3 (cs) 1999-02-17
HUP9900170A3 (en) 1999-11-29
GT199600072A (es) 1998-02-14
NO980862D0 (no) 1998-02-27
KR19990044232A (ko) 1999-06-25
AR003985A1 (es) 1998-09-30
MY113874A (en) 2002-06-29
KR100343909B1 (ko) 2003-04-10
AP9600853A0 (en) 1996-10-31
NO980862L (no) 1998-02-27
MA23966A1 (fr) 1997-04-01
WO1997007800A1 (en) 1997-03-06
CN1190889A (zh) 1998-08-19
MX9801664A (es) 1998-08-30

Similar Documents

Publication Publication Date Title
DK1235826T3 (da) Quinuclidinacrylamider
CZ2019248A3 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
DE60025369D1 (de) Unterchlorige säure enthaltendes superoxidiertes wasser zur behandlung von wunden
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
ES527027A0 (es) Procedimiento para preparar imidazolilalquiltien-2-il-tetrahidropiridazinas
DK0772600T3 (da) 1,2-substituerede imidazolylforbindelser til behandling af inflammation
BRPI0213348A2 (pt) sistema para desinfectar água usando radiação ultravioleta(uv)
HUP0204182A3 (en) Use of fumaric acid derivatives for treating mitochondrial diseases
AR034556A1 (es) Un derivado de fenilalanina, una composicion farmaceutica que comprende al derivado de fenilalanina, el uso del derivado y proceso para preparar dicho derivado
DK0882049T3 (da) Eventuelt substituerede 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-quinolincarboxylsyrer og deres derivater
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
DK103384D0 (da) Quinoloncarboxylsyrer eller salte eller hydrater deraf, deres fremstilling og anvendelse som antibakterielle midler
EA199900526A1 (ru) Применение производных 7-(2-окса-5,8-диазабицикло[4,3,0] нон-8-ил)-хинолонкарбоновой кислоты и -нафтиридонкарбоновой кислоты для лечения helicobacter pylori- инфекций и связанных с ними гастродуоденальных заболеваний
ITMI941693A0 (it) Sali organici idrosolubili della creatina
ATE399782T1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
PE12598A1 (es) Formas zwitterionicas de trovafloxacina
BR0114697A (pt) Derivados em ponte de piperazina
NO20012541D0 (no) Anvendelse av fosfonomaursyrederivater for behandling av infeksjoner
NO923393L (no) Fremgangsmaate for inhibering av korrosjon i broenner som syrebehandle
NO976043D0 (no) Terapautiske forbindelser
ES2084181T3 (es) Composiciones farmaceuticas para usar en el tratamiento del sida.
FI841604A0 (fi) Med baser bildade piroxicamsalter utfaellda pao en farmaceutiskt godtagbar baerare.
HUP9801925A1 (hu) Nátrium/hidrogén-csere inhibítorok alkalmazása protozoák által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
AR011178A1 (es) Compuesto de sal de sodio de (acido (e) 4,6-dicloro-3-(2-oxo-1- fenilpirrolidin-3-ilideno-metil)-1h-indol-2-carboxilico en su forma hidratada,proceso para su preparacion, composicion farmaceutica que lo contiene y metodo de tratamiento utilizando dicho compuesto

Legal Events

Date Code Title Description
FC Refusal